Osaka, Japan

Shigenobu Nishiguchi

This inventor holds 2 USPTO granted patents. Top assignees: The University of Tokyo, Towa Pharmaceutical Co., Ltd.. Active years: 2019-2020.


Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2019-2020

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Shigenobu Nishiguchi: Innovator in Proton Pump Inhibitor Compounds

Introduction

Shigenobu Nishiguchi is a prominent inventor based in Osaka, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of proton pump inhibitors. With a total of 2 patents, his work has had a notable impact on the industry.

Latest Patents

Nishiguchi's latest patents focus on methods for producing highly pure optically active proton pump inhibitor compounds. His innovative approach allows for the safe and inexpensive production of these compounds in high yield and enantioselectivity. The methods involve oxidizing a sulfide with hydrogen peroxide using an iron salt in the presence of a chiral ligand. This process is crucial for creating optically active sulfoxides, which are essential in the pharmaceutical industry.

Career Highlights

Throughout his career, Nishiguchi has worked with esteemed institutions such as The University of Tokyo and Towa Pharmaceutical Co., Ltd. His expertise in the field has led to advancements in the production of pharmaceutical compounds, particularly those that require optical activity.

Collaborations

Nishiguchi has collaborated with notable professionals in his field, including Eiichi Nakamura and Laurean Ilies. These partnerships have further enhanced his research and development efforts in the pharmaceutical sector.

Conclusion

Shigenobu Nishiguchi's contributions to the field of proton pump inhibitors demonstrate his innovative spirit and dedication to advancing pharmaceutical science. His patents and collaborations reflect a commitment to improving drug production methods, ultimately benefiting the healthcare industry.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…